-
1
-
-
0036302288
-
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
-
Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.
-
(2002)
Gastroenterology
, vol.123
, pp. 134-140
-
-
Bugianesi, E.1
Leone, N.2
Vanni, E.3
-
2
-
-
84890562275
-
Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
-
Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110–7.
-
(2014)
J Hepatol
, vol.60
, pp. 110-117
-
-
Dyson, J.1
Jaques, B.2
Chattopadyhay, D.3
-
3
-
-
80053581540
-
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States
-
Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249–53.
-
(2011)
Gastroenterology
, vol.141
, pp. 1249-1253
-
-
Charlton, M.R.1
Burns, J.M.2
Pedersen, R.A.3
-
4
-
-
0037221394
-
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States
-
Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71–9.
-
(2003)
Gastroenterology
, vol.124
, pp. 71-79
-
-
Ruhl, C.E.1
Everhart, J.E.2
-
5
-
-
10644220306
-
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
-
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
-
(2004)
Hepatology
, vol.40
, pp. 1387-1395
-
-
Browning, J.D.1
Szczepaniak, L.S.2
Dobbins, R.3
-
6
-
-
84983123731
-
Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups
-
Non-Alcoholic Fatty Liver Disease Study G, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015; 47: 997–1006.
-
(2015)
Dig Liver Dis
, vol.47
, pp. 997-1006
-
-
Lonardo, A.1
Bellentani, S.2
Argo, C.K.3
Ballestri, S.4
Byrne, C.D.5
-
7
-
-
0033231294
-
Association of nonalcoholic fatty liver disease with insulin resistance
-
Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
-
(1999)
Am J Med
, vol.107
, pp. 450-455
-
-
Marchesini, G.1
Brizi, M.2
Morselli-Labate, A.M.3
-
8
-
-
0035431018
-
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome
-
Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–50.
-
(2001)
Diabetes
, vol.50
, pp. 1844-1850
-
-
Marchesini, G.1
Brizi, M.2
Bianchi, G.3
-
9
-
-
0037382786
-
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
-
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.
-
(2003)
Hepatology
, vol.37
, pp. 917-923
-
-
Marchesini, G.1
Bugianesi, E.2
Forlani, G.3
-
10
-
-
84921487729
-
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
-
Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506–14.
-
(2015)
Hepatology
, vol.61
, pp. 506-514
-
-
Dongiovanni, P.1
Petta, S.2
Maglio, C.3
-
11
-
-
84927615859
-
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
-
Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014; 20: 12945–55.
-
(2014)
World J Gastroenterol
, vol.20
, pp. 12945-12955
-
-
Dongiovanni, P.1
Romeo, S.2
Valenti, L.3
-
12
-
-
84991797701
-
The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
-
Dongiovanni P, Rametta R, Meroni M, Valenti L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2015; 10: 1–14.
-
(2015)
Expert Rev Gastroenterol Hepatol
, vol.10
, pp. 1-14
-
-
Dongiovanni, P.1
Rametta, R.2
Meroni, M.3
Valenti, L.4
-
13
-
-
84902672359
-
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
-
Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–10.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 901-910
-
-
Yki-Jarvinen, H.1
-
14
-
-
0024160877
-
Banting lecture 1988. Role of insulin resistance in human disease
-
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
-
(1988)
Diabetes
, vol.37
, pp. 1595-1607
-
-
Reaven, G.M.1
-
15
-
-
84918819322
-
Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease
-
Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371: 1131–41.
-
(2014)
N Engl J Med
, vol.371
, pp. 1131-1141
-
-
Shulman, G.I.1
-
16
-
-
0034072554
-
Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans
-
Roden M, Stingl H, Chandramouli V, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49: 701–7.
-
(2000)
Diabetes
, vol.49
, pp. 701-707
-
-
Roden, M.1
Stingl, H.2
Chandramouli, V.3
-
17
-
-
0033890616
-
Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study
-
Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49: 1367–73.
-
(2000)
Diabetes
, vol.49
, pp. 1367-1373
-
-
Gastaldelli, A.1
Baldi, S.2
Pettiti, M.3
-
18
-
-
0042320958
-
Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans
-
Adkins A, Basu R, Persson M, et al. Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans. Diabetes 2003; 52: 2213–20.
-
(2003)
Diabetes
, vol.52
, pp. 2213-2220
-
-
Adkins, A.1
Basu, R.2
Persson, M.3
-
19
-
-
65549151428
-
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans
-
Kantartzis K, Machicao F, Machann J, et al. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci 2009; 116: 531–7.
-
(2009)
Clin Sci
, vol.116
, pp. 531-537
-
-
Kantartzis, K.1
Machicao, F.2
Machann, J.3
-
20
-
-
0036312905
-
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men
-
Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–8.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 3023-3028
-
-
Seppala-Lindroos, A.1
Vehkavaara, S.2
Hakkinen, A.M.3
-
21
-
-
20944450486
-
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
-
Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634–42.
-
(2005)
Diabetologia
, vol.48
, pp. 634-642
-
-
Bugianesi, E.1
Gastaldelli, A.2
Vanni, E.3
-
22
-
-
64649104158
-
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
-
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–95.
-
(2009)
Diabetes
, vol.58
, pp. 773-795
-
-
Defronzo, R.A.1
-
23
-
-
84908254009
-
beta-Cell function in type 2 diabetes
-
Ferrannini E, Mari A. beta-Cell function in type 2 diabetes. Metabolism 2014; 63: 1217–27.
-
(2014)
Metabolism
, vol.63
, pp. 1217-1227
-
-
Ferrannini, E.1
Mari, A.2
-
24
-
-
18244382304
-
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
-
Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–51.
-
(2005)
J Clin Invest
, vol.115
, pp. 1343-1351
-
-
Donnelly, K.L.1
Smith, C.I.2
Schwarzenberg, S.J.3
-
25
-
-
77957375969
-
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
-
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341–50.
-
(2010)
N Engl J Med
, vol.363
, pp. 1341-1350
-
-
Targher, G.1
Day, C.P.2
Bonora, E.3
-
26
-
-
70349326750
-
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
-
Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430–5.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 15430-15435
-
-
Fabbrini, E.1
Magkos, F.2
Mohammed, B.S.3
-
27
-
-
34547514221
-
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
-
Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496–506.
-
(2007)
Gastroenterology
, vol.133
, pp. 496-506
-
-
Gastaldelli, A.1
Cusi, K.2
Pettiti, M.3
-
28
-
-
84877854022
-
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease
-
Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544–60.
-
(2013)
Nutrients
, vol.5
, pp. 1544-1560
-
-
Gaggini, M.1
Morelli, M.2
Buzzigoli, E.3
-
29
-
-
0034033372
-
Visceral fat and insulin resistance–causative or correlative?
-
Frayn KN. Visceral fat and insulin resistance–causative or correlative? Br J Nutr 2000; 83(Suppl. 1): S71–7.
-
(2000)
Br J Nutr
, vol.83
, pp. S71-S77
-
-
Frayn, K.N.1
-
30
-
-
84860420859
-
Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus
-
Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 93(Suppl. 1): S60–5.
-
(2011)
Diabetes Res Clin Pract
, vol.93
, pp. S60-S65
-
-
Gastaldelli, A.1
-
31
-
-
18844432308
-
Adiponectin and adiponectin receptors
-
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439–51.
-
(2005)
Endocr Rev
, vol.26
, pp. 439-451
-
-
Kadowaki, T.1
Yamauchi, T.2
-
32
-
-
79951810722
-
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
-
Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313–26.
-
(2011)
Metabolism
, vol.60
, pp. 313-326
-
-
Polyzos, S.A.1
Toulis, K.A.2
Goulis, D.G.3
Zavos, C.4
Kountouras, J.5
-
33
-
-
70349238777
-
Adipokines in liver diseases
-
Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957–69.
-
(2009)
Hepatology
, vol.50
, pp. 957-969
-
-
Marra, F.1
Bertolani, C.2
-
34
-
-
0025740427
-
Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis
-
Petrides AS, Groop LC, Riely CA, Defronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991; 88: 561–70.
-
(1991)
J Clin Invest
, vol.88
, pp. 561-570
-
-
Petrides, A.S.1
Groop, L.C.2
Riely, C.A.3
Defronzo, R.A.4
-
35
-
-
39049102073
-
Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients
-
Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444–50.
-
(2008)
Diabetologia
, vol.51
, pp. 444-450
-
-
Targher, G.1
Bertolini, L.2
Rodella, S.3
-
36
-
-
84939200165
-
Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis
-
Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int 2015; 2015: 460190.
-
(2015)
Biomed Res Int
, vol.2015
, pp. 460190
-
-
Dongiovanni, P.1
Romeo, S.2
Valenti, L.3
-
37
-
-
0037267345
-
The association of fatty liver and diabetes risk
-
Okamoto M, Takeda Y, Yoda Y, et al. The association of fatty liver and diabetes risk. J Epidemiol 2003; 13: 15–21.
-
(2003)
J Epidemiol
, vol.13
, pp. 15-21
-
-
Okamoto, M.1
Takeda, Y.2
Yoda, Y.3
-
38
-
-
34347402532
-
Effects of nonalcoholic fatty liver disease on the development of metabolic disorders
-
Fan JG, Li F, Cai XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22: 1086–91.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 1086-1091
-
-
Fan, J.G.1
Li, F.2
Cai, X.B.3
-
39
-
-
36048934639
-
Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men
-
Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940–4.
-
(2007)
Diabetes Care
, vol.30
, pp. 2940-2944
-
-
Shibata, M.1
Kihara, Y.2
Taguchi, M.3
Tashiro, M.4
Otsuki, M.5
-
40
-
-
41749083027
-
Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults
-
Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476–81.
-
(2008)
Diabet Med
, vol.25
, pp. 476-481
-
-
Kim, C.H.1
Park, J.Y.2
Lee, K.U.3
Kim, J.H.4
Kim, H.K.5
-
41
-
-
76149092159
-
Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup
-
Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352–6.
-
(2010)
J Gastroenterol Hepatol
, vol.25
, pp. 352-356
-
-
Yamada, T.1
Fukatsu, M.2
Suzuki, S.3
-
42
-
-
79956074978
-
Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study
-
Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727–9.
-
(2011)
Diabetes Care
, vol.34
, pp. 727-729
-
-
Bae, J.C.1
Rhee, E.J.2
Lee, W.Y.3
-
43
-
-
84876105171
-
Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study
-
Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57: 1378–83.
-
(2013)
Hepatology
, vol.57
, pp. 1378-1383
-
-
Park, S.K.1
Seo, M.H.2
Shin, H.C.3
Ryoo, J.H.4
-
44
-
-
84862075971
-
Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes
-
Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717–22.
-
(2012)
Diabetes Care
, vol.35
, pp. 717-722
-
-
Sung, K.C.1
Jeong, W.S.2
Wild, S.H.3
Byrne, C.D.4
-
45
-
-
84871643501
-
Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus
-
Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013; 28: 142–7.
-
(2013)
J Gastroenterol Hepatol
, vol.28
, pp. 142-147
-
-
Kasturiratne, A.1
Weerasinghe, S.2
Dassanayake, A.S.3
-
46
-
-
84889658153
-
Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population
-
Chang Y, Jung HS, Yun KE, et al. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013; 108: 1861–8.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 1861-1868
-
-
Chang, Y.1
Jung, H.S.2
Yun, K.E.3
-
47
-
-
84883686923
-
Resolution of fatty liver and risk of incident diabetes
-
Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98: 3637–43.
-
(2013)
J Clin Endocrinol Metab
, vol.98
, pp. 3637-3643
-
-
Sung, K.C.1
Wild, S.H.2
Byrne, C.D.3
-
48
-
-
84962469252
-
Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of Type 2 diabetes
-
Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of Type 2 diabetes. Diabetes Care 2015; 38: 1673–9.
-
(2015)
Diabetes Care
, vol.38
, pp. 1673-1679
-
-
Yamazaki, H.1
Tsuboya, T.2
Tsuji, K.3
Dohke, M.4
Maguchi, H.5
-
49
-
-
84955489581
-
The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals
-
Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275–83.
-
(2016)
Liver Int
, vol.36
, pp. 275-283
-
-
Fukuda, T.1
Hamaguchi, M.2
Kojima, T.3
-
50
-
-
84937858836
-
Liver fat, statin use, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis
-
Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015; 242: 211–7.
-
(2015)
Atherosclerosis
, vol.242
, pp. 211-217
-
-
Shah, R.V.1
Allison, M.A.2
Lima, J.A.3
-
51
-
-
84945447081
-
Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study
-
Ming J, Xu S, Gao B, et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int 2015; 35: 2401–7.
-
(2015)
Liver Int
, vol.35
, pp. 2401-2407
-
-
Ming, J.1
Xu, S.2
Gao, B.3
-
52
-
-
84940121986
-
Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus
-
Li WD, Fu KF, Li GM, et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol 2015; 21: 9607–13.
-
(2015)
World J Gastroenterol
, vol.21
, pp. 9607-9613
-
-
Li, W.D.1
Fu, K.F.2
Li, G.M.3
-
53
-
-
84875259571
-
Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study
-
Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44: 115–20.
-
(2013)
Arch Med Res
, vol.44
, pp. 115-120
-
-
Choi, J.H.1
Rhee, E.J.2
Bae, J.C.3
-
54
-
-
84964510429
-
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
-
Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31: 936–44.
-
(2016)
J Gastroenterol Hepatol
, vol.31
, pp. 936-944
-
-
Ballestri, S.1
Zona, S.2
Targher, G.3
-
55
-
-
33750606061
-
Long-term follow-up of patients with NAFLD and elevated liver enzymes
-
Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
-
(2006)
Hepatology
, vol.44
, pp. 865-873
-
-
Ekstedt, M.1
Franzen, L.E.2
Mathiesen, U.L.3
-
56
-
-
77954956697
-
Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
-
Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010; 21: 329–36.
-
(2010)
Curr Opin Lipidol
, vol.21
, pp. 329-336
-
-
Savage, D.B.1
Semple, R.K.2
-
57
-
-
84862023939
-
Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression
-
Haas JT, Miao J, Chanda D, et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab 2012; 15: 873–84.
-
(2012)
Cell Metab
, vol.15
, pp. 873-884
-
-
Haas, J.T.1
Miao, J.2
Chanda, D.3
-
58
-
-
62749188867
-
The role of the lipogenic pathway in the development of hepatic steatosis
-
Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008; 34(Pt 2): 643–8.
-
(2008)
Diabetes Metab
, vol.34
, pp. 643-648
-
-
Postic, C.1
Girard, J.2
-
59
-
-
0036251153
-
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
-
Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31.
-
(2002)
J Clin Invest
, vol.109
, pp. 1125-1131
-
-
Horton, J.D.1
Goldstein, J.L.2
Brown, M.S.3
-
60
-
-
79961165137
-
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway
-
Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146: 408–20.
-
(2011)
Cell
, vol.146
, pp. 408-420
-
-
Peterson, T.R.1
Sengupta, S.S.2
Harris, T.E.3
-
61
-
-
50049116472
-
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
-
Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008; 8: 224–36.
-
(2008)
Cell Metab
, vol.8
, pp. 224-236
-
-
Porstmann, T.1
Santos, C.R.2
Griffiths, B.3
-
62
-
-
35248816945
-
The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
-
Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007; 56: 1500–7.
-
(2007)
Metabolism
, vol.56
, pp. 1500-1507
-
-
Brown, N.F.1
Stefanovic-Racic, M.2
Sipula, I.J.3
Perdomo, G.4
-
63
-
-
79959996153
-
Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways
-
Yecies JL, Zhang HH, Menon S, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011; 14: 21–32.
-
(2011)
Cell Metab
, vol.14
, pp. 21-32
-
-
Yecies, J.L.1
Zhang, H.H.2
Menon, S.3
-
64
-
-
77649264504
-
Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis
-
Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3441–6.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 3441-3446
-
-
Li, S.1
Brown, M.S.2
Goldstein, J.L.3
-
65
-
-
33244464562
-
Critical nodes in signalling pathways: insights into insulin action
-
Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85–96.
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 85-96
-
-
Taniguchi, C.M.1
Emanuelli, B.2
Kahn, C.R.3
-
66
-
-
84857934301
-
Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1
-
Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med 2012; 18: 388–95.
-
(2012)
Nat Med
, vol.18
, pp. 388-395
-
-
Lu, M.1
Wan, M.2
Leavens, K.F.3
-
67
-
-
79959962745
-
Hormonal regulation of hepatic glucose production in health and disease
-
Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011; 14: 9–19.
-
(2011)
Cell Metab
, vol.14
, pp. 9-19
-
-
Lin, H.V.1
Accili, D.2
-
68
-
-
0035185021
-
The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
-
Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001; 108: 1359–67.
-
(2001)
J Clin Invest
, vol.108
, pp. 1359-1367
-
-
Nakae, J.1
Kitamura, T.2
Silver, D.L.3
Accili, D.4
-
69
-
-
20144365700
-
Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes
-
Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005; 280: 20589–95.
-
(2005)
J Biol Chem
, vol.280
, pp. 20589-20595
-
-
Frescas, D.1
Valenti, L.2
Accili, D.3
-
70
-
-
0034680839
-
Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity
-
Schmoll D, Walker KS, Alessi DR, et al. Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem 2000; 275: 36324–33.
-
(2000)
J Biol Chem
, vol.275
, pp. 36324-36333
-
-
Schmoll, D.1
Walker, K.S.2
Alessi, D.R.3
-
71
-
-
33744515637
-
FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression
-
Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281: 10105–17.
-
(2006)
J Biol Chem
, vol.281
, pp. 10105-10117
-
-
Zhang, W.1
Patil, S.2
Chauhan, B.3
-
72
-
-
0029859045
-
Regulation of gene expression by insulin
-
O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev 1996; 76: 1109–61.
-
(1996)
Physiol Rev
, vol.76
, pp. 1109-1161
-
-
O'Brien, R.M.1
Granner, D.K.2
-
73
-
-
79961173038
-
Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner
-
Pajvani UB, Shawber CJ, Samuel VT, et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011; 17: 961–7.
-
(2011)
Nat Med
, vol.17
, pp. 961-967
-
-
Pajvani, U.B.1
Shawber, C.J.2
Samuel, V.T.3
-
74
-
-
84882245596
-
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability
-
Pajvani UB, Qiang L, Kangsamaksin T, et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013; 19: 1054–60.
-
(2013)
Nat Med
, vol.19
, pp. 1054-1060
-
-
Pajvani, U.B.1
Qiang, L.2
Kangsamaksin, T.3
-
75
-
-
84862909028
-
Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice
-
Zhang K, Li L, Qi Y, et al. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 2012; 153: 631–46.
-
(2012)
Endocrinology
, vol.153
, pp. 631-646
-
-
Zhang, K.1
Li, L.2
Qi, Y.3
-
76
-
-
79954576666
-
Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene
-
Tao R, Wei D, Gao H, et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011; 286: 14681–90.
-
(2011)
J Biol Chem
, vol.286
, pp. 14681-14690
-
-
Tao, R.1
Wei, D.2
Gao, H.3
-
77
-
-
84922754155
-
Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors
-
Haeusler RA, Hartil K, Vaitheesvaran B, et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun 2014; 5: 5190.
-
(2014)
Nat Commun
, vol.5
, pp. 5190
-
-
Haeusler, R.A.1
Hartil, K.2
Vaitheesvaran, B.3
-
78
-
-
71449091240
-
Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin
-
Liu HY, Han J, Cao SY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem 2009; 284: 31484–92.
-
(2009)
J Biol Chem
, vol.284
, pp. 31484-31492
-
-
Liu, H.Y.1
Han, J.2
Cao, S.Y.3
-
79
-
-
84879010418
-
S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice: lipids as usual suspects
-
Ceuninck FD, Kargar C, Charton Y, et al. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice: lipids as usual suspects. Br J Pharmacol 2013; 169: 999–1010.
-
(2013)
Br J Pharmacol
, vol.169
, pp. 999-1010
-
-
Ceuninck, F.D.1
Kargar, C.2
Charton, Y.3
-
80
-
-
84871604441
-
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans
-
De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013; 168: 339–53.
-
(2013)
Br J Pharmacol
, vol.168
, pp. 339-353
-
-
De Ceuninck, F.1
Kargar, C.2
Ilic, C.3
-
81
-
-
13844312400
-
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
-
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–101.
-
(2005)
Science
, vol.307
, pp. 1098-1101
-
-
Sarbassov, D.D.1
Guertin, D.A.2
Ali, S.M.3
Sabatini, D.M.4
-
83
-
-
15944406764
-
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth
-
Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13–24.
-
(2005)
Mol Cell
, vol.18
, pp. 13-24
-
-
Gao, T.1
Furnari, F.2
Newton, A.C.3
-
84
-
-
33947203621
-
PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms
-
Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007; 25: 917–31.
-
(2007)
Mol Cell
, vol.25
, pp. 917-931
-
-
Brognard, J.1
Sierecki, E.2
Gao, T.3
Newton, A.C.4
-
86
-
-
84898961798
-
PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice
-
e10.
-
Li X, Stevens PD, Liu J, et al. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 2014; 146: 1301–12.e10.
-
(2014)
Gastroenterology
, vol.146
, pp. 1301-1312
-
-
Li, X.1
Stevens, P.D.2
Liu, J.3
-
87
-
-
84899459754
-
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor beta-activated stem cells
-
Ghalali A, Ye ZW, Hogberg J, Stenius U. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor beta-activated stem cells. J Biol Chem 2014; 289: 11601–15.
-
(2014)
J Biol Chem
, vol.289
, pp. 11601-11615
-
-
Ghalali, A.1
Ye, Z.W.2
Hogberg, J.3
Stenius, U.4
-
88
-
-
84899821715
-
Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt
-
Wang P, Zhou Z, Hu A, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 2014; 54: 378–91.
-
(2014)
Mol Cell
, vol.54
, pp. 378-391
-
-
Wang, P.1
Zhou, Z.2
Hu, A.3
-
89
-
-
84953932016
-
mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2
-
Kim K, Qiang L, Hayden MS, et al. mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. Nat Commun 2016; 7: 10255.
-
(2016)
Nat Commun
, vol.7
, pp. 10255
-
-
Kim, K.1
Qiang, L.2
Hayden, M.S.3
-
90
-
-
79952312698
-
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma
-
Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071–83.
-
(2011)
Gastroenterology
, vol.140
, pp. 1071-1083
-
-
Calvisi, D.F.1
Wang, C.2
Ho, C.3
-
91
-
-
84884402458
-
SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice
-
Li L, Wang C, Calvisi DF, et al. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice. PLoS ONE 2013; 8: e75104.
-
(2013)
PLoS ONE
, vol.8
-
-
Li, L.1
Wang, C.2
Calvisi, D.F.3
-
92
-
-
84860454425
-
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c
-
Hagiwara A, Cornu M, Cybulski N, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012; 15: 725–38.
-
(2012)
Cell Metab
, vol.15
, pp. 725-738
-
-
Hagiwara, A.1
Cornu, M.2
Cybulski, N.3
-
93
-
-
70249108137
-
The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis
-
Guo S, Copps KD, Dong X, et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009; 29: 5070–83.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 5070-5083
-
-
Guo, S.1
Copps, K.D.2
Dong, X.3
-
94
-
-
70350417158
-
Akt2 is required for hepatic lipid accumulation in models of insulin resistance
-
Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 2009; 10: 405–18.
-
(2009)
Cell Metab
, vol.10
, pp. 405-418
-
-
Leavens, K.F.1
Easton, R.M.2
Shulman, G.I.3
Previs, S.F.4
Birnbaum, M.J.5
-
95
-
-
84930216520
-
Pathogenesis of selective insulin resistance in isolated hepatocytes
-
Cook JR, Langlet F, Kido Y, Accili D. Pathogenesis of selective insulin resistance in isolated hepatocytes. J Biol Chem 2015; 290: 13972–80.
-
(2015)
J Biol Chem
, vol.290
, pp. 13972-13980
-
-
Cook, J.R.1
Langlet, F.2
Kido, Y.3
Accili, D.4
-
96
-
-
80052947518
-
NASH animal models: are we there yet?
-
Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol 2011; 55: 941–3.
-
(2011)
J Hepatol
, vol.55
, pp. 941-943
-
-
Kohli, R.1
Feldstein, A.E.2
-
97
-
-
50049097587
-
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
-
Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008; 49: 1068–76.
-
(2008)
J Lipid Res
, vol.49
, pp. 1068-1076
-
-
Rinella, M.E.1
Elias, M.S.2
Smolak, R.R.3
-
98
-
-
45749114635
-
Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis
-
Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355–62.
-
(2008)
Diabetes
, vol.57
, pp. 1355-1362
-
-
Valenti, L.1
Rametta, R.2
Dongiovanni, P.3
-
99
-
-
84880255942
-
Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects
-
Rametta R, Mozzi E, Dongiovanni P, et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes 2013; 37: 986–92.
-
(2013)
Int J Obes
, vol.37
, pp. 986-992
-
-
Rametta, R.1
Mozzi, E.2
Dongiovanni, P.3
-
100
-
-
80053627289
-
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
-
Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011; 108: 16381–5.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 16381-16385
-
-
Kumashiro, N.1
Erion, D.M.2
Zhang, D.3
-
101
-
-
84959104290
-
Ceramides dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease
-
Luukkonen PK, Zhou Y, Sadevirta S, et al. Ceramides dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1167–75.
-
(2016)
J Hepatol
, vol.64
, pp. 1167-1175
-
-
Luukkonen, P.K.1
Zhou, Y.2
Sadevirta, S.3
-
102
-
-
84907984591
-
CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance
-
Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014; 20: 687–95.
-
(2014)
Cell Metab
, vol.20
, pp. 687-695
-
-
Raichur, S.1
Wang, S.T.2
Chan, P.W.3
-
103
-
-
84890116926
-
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
-
Oresic M, Hyotylainen T, Kotronen A, et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013; 56: 2266–74.
-
(2013)
Diabetologia
, vol.56
, pp. 2266-2274
-
-
Oresic, M.1
Hyotylainen, T.2
Kotronen, A.3
-
104
-
-
84882959698
-
Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver
-
Lehmann R, Franken H, Dammeier S, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013; 36: 2331–8.
-
(2013)
Diabetes Care
, vol.36
, pp. 2331-2338
-
-
Lehmann, R.1
Franken, H.2
Dammeier, S.3
-
105
-
-
3142677943
-
SREBP-1c mediates the insulin-dependent hepatic glucokinase expression
-
Kim SY, Kim HI, Kim TH, et al. SREBP-1c mediates the insulin-dependent hepatic glucokinase expression. J Biol Chem 2004; 279: 30823–9.
-
(2004)
J Biol Chem
, vol.279
, pp. 30823-30829
-
-
Kim, S.Y.1
Kim, H.I.2
Kim, T.H.3
-
106
-
-
79960086105
-
Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans
-
Peter A, Stefan N, Cegan A, et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011; 96: E1126–30.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. E1126-E1130
-
-
Peter, A.1
Stefan, N.2
Cegan, A.3
-
107
-
-
84891762279
-
Hepatic notch signaling correlates with insulin resistance and nonalcoholic Fatty liver disease
-
Valenti L, Mendoza RM, Rametta R, et al. Hepatic notch signaling correlates with insulin resistance and nonalcoholic Fatty liver disease. Diabetes 2013; 62: 4052–62.
-
(2013)
Diabetes
, vol.62
, pp. 4052-4062
-
-
Valenti, L.1
Mendoza, R.M.2
Rametta, R.3
-
108
-
-
84945321040
-
Genetics of nonalcoholic fatty liver disease
-
Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016; 65: 1026–37.
-
(2016)
Metabolism
, vol.65
, pp. 1026-1037
-
-
Dongiovanni, P.1
Valenti, L.2
-
109
-
-
56749096610
-
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
-
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5.
-
(2008)
Nat Genet
, vol.40
, pp. 1461-1465
-
-
Romeo, S.1
Kozlitina, J.2
Xing, C.3
-
110
-
-
79957462315
-
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
-
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–94.
-
(2011)
Hepatology
, vol.53
, pp. 1883-1894
-
-
Sookoian, S.1
Pirola, C.J.2
-
111
-
-
84887553152
-
PNPLA3 I148M polymorphism and progressive liver disease
-
Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19: 6969–78.
-
(2013)
World J Gastroenterol
, vol.19
, pp. 6969-6978
-
-
Dongiovanni, P.1
Donati, B.2
Fares, R.3
-
112
-
-
77949895032
-
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis
-
He S, Mcphaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706–15.
-
(2010)
J Biol Chem
, vol.285
, pp. 6706-6715
-
-
He, S.1
Mcphaul, C.2
Li, J.Z.3
-
113
-
-
84903996547
-
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
-
Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014; 23: 4077–85.
-
(2014)
Hum Mol Genet
, vol.23
, pp. 4077-4085
-
-
Pirazzi, C.1
Valenti, L.2
Motta, B.M.3
-
114
-
-
84897430331
-
PNPLA3 mediates hepatocyte triacylglycerol remodeling
-
Ruhanen H, Perttila J, Holtta-Vuori M, et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 2014; 55: 739–46.
-
(2014)
J Lipid Res
, vol.55
, pp. 739-746
-
-
Ruhanen, H.1
Perttila, J.2
Holtta-Vuori, M.3
-
115
-
-
84920955177
-
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
-
Smagris E, Basuray S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108–18.
-
(2015)
Hepatology
, vol.61
, pp. 108-118
-
-
Smagris, E.1
Basuray, S.2
Li, J.3
-
116
-
-
84954290324
-
The rs2294918 E434K variant modulates PNPLA3 expression and liver damage
-
Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates PNPLA3 expression and liver damage. Hepatology 2016; 63: 787–98.
-
(2016)
Hepatology
, vol.63
, pp. 787-798
-
-
Donati, B.1
Motta, B.M.2
Pingitore, P.3
-
117
-
-
84891810442
-
Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity
-
Hyysalo J, Gopalacharyulu P, Bian H, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 2013; 63: 312–22.
-
(2013)
Diabetes
, vol.63
, pp. 312-322
-
-
Hyysalo, J.1
Gopalacharyulu, P.2
Bian, H.3
-
118
-
-
84926660045
-
PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans
-
Peter A, Kovarova M, Nadalin S, et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 2014; 57: 2103–7.
-
(2014)
Diabetologia
, vol.57
, pp. 2103-2107
-
-
Peter, A.1
Kovarova, M.2
Nadalin, S.3
-
119
-
-
84862491622
-
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant
-
Palmer CN, Maglio C, Pirazzi C, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012; 7: e39362.
-
(2012)
PLoS ONE
, vol.7
-
-
Palmer, C.N.1
Maglio, C.2
Pirazzi, C.3
-
120
-
-
84898058711
-
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
-
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352–6.
-
(2014)
Nat Genet
, vol.46
, pp. 352-356
-
-
Kozlitina, J.1
Smagris, E.2
Stender, S.3
-
121
-
-
84902602986
-
TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content
-
Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 2014; 111: 8913–8.
-
(2014)
Proc Natl Acad Sci USA
, vol.111
, pp. 8913-8918
-
-
Mahdessian, H.1
Taxiarchis, A.2
Popov, S.3
-
122
-
-
84898058547
-
Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk
-
Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345–51.
-
(2014)
Nat Genet
, vol.46
, pp. 345-351
-
-
Holmen, O.L.1
Zhang, H.2
Fan, Y.3
-
123
-
-
84969277864
-
Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins
-
Smagris E, Gilyard S, Basuray S, Cohen JC, HOBBS HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016; 291: 10659–76.
-
(2016)
J Biol Chem
, vol.291
, pp. 10659-10676
-
-
Smagris, E.1
Gilyard, S.2
Basuray, S.3
Cohen, J.C.4
Hobbs, H.5
-
124
-
-
84955203053
-
The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis
-
Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology 2015; 62: 1742–56.
-
(2015)
Hepatology
, vol.62
, pp. 1742-1756
-
-
Pirola, C.J.1
Sookoian, S.2
-
125
-
-
84964334172
-
The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent
-
Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016; 150: 1219–230.
-
(2016)
Gastroenterology
, vol.150
, pp. 1219-1230
-
-
Mancina, R.M.1
Dongiovanni, P.2
Petta, S.3
-
126
-
-
79953745343
-
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits
-
Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
-
(2011)
PLoS Genet
, vol.7
-
-
Speliotes, E.K.1
Yerges-Armstrong, L.M.2
Wu, J.3
-
127
-
-
84857398069
-
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents
-
Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2011; 55: 781–9.
-
(2011)
Hepatology
, vol.55
, pp. 781-789
-
-
Santoro, N.1
Zhang, C.K.2
Zhao, H.3
-
128
-
-
84896824930
-
Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease
-
Petta S, Miele L, Bugianesi E, et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease. PLoS ONE 2014; 9: e87523.
-
(2014)
PLoS ONE
, vol.9
-
-
Petta, S.1
Miele, L.2
Bugianesi, E.3
-
129
-
-
84857429794
-
Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms
-
Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 2012; 55: 661–3.
-
(2012)
Hepatology
, vol.55
, pp. 661-663
-
-
Valenti, L.1
Alisi, A.2
Nobili, V.3
-
130
-
-
70349980881
-
The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver
-
Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18: 4081–8.
-
(2009)
Hum Mol Genet
, vol.18
, pp. 4081-4088
-
-
Beer, N.L.1
Tribble, N.D.2
McCulloch, L.J.3
-
131
-
-
84926410232
-
Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia
-
Di Filippo M, Moulin P, Roy P, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 2014; 61: 891–902.
-
(2014)
J Hepatol
, vol.61
, pp. 891-902
-
-
Di Filippo, M.1
Moulin, P.2
Roy, P.3
-
132
-
-
84881025772
-
A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia
-
Cefalu AB, Pirruccello JP, Noto D, et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33: 2021–5.
-
(2013)
Arterioscler Thromb Vasc Biol
, vol.33
, pp. 2021-2025
-
-
Cefalu, A.B.1
Pirruccello, J.P.2
Noto, D.3
-
133
-
-
77953893410
-
Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia
-
Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139: 149–53.
-
(2010)
Gastroenterology
, vol.139
, pp. 149-153
-
-
Amaro, A.1
Fabbrini, E.2
Kars, M.3
-
134
-
-
77149168465
-
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
-
Dongiovanni P, Valenti L, Rametta R, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267–73.
-
(2010)
Gut
, vol.59
, pp. 267-273
-
-
Dongiovanni, P.1
Valenti, L.2
Rametta, R.3
-
135
-
-
84929266699
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
-
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956–65.
-
(2015)
Lancet
, vol.385
, pp. 956-965
-
-
Neuschwander-Tetri, B.A.1
Loomba, R.2
Sanyal, A.J.3
-
136
-
-
78651260799
-
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
-
Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55–63.
-
(2011)
Nat Med
, vol.17
, pp. 55-63
-
-
Holland, W.L.1
Miller, R.A.2
Wang, Z.V.3
|